Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 57, Issue 20, Pages 8224-8237Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm500101h
Keywords
-
Categories
Funding
- NSF [CHE-1152317]
- National Center for Advancing Translational Sciences, National Institutes of Health [UL1 TR000038]
- New York University
- Direct For Mathematical & Physical Scien
- Division Of Chemistry [1152317] Funding Source: National Science Foundation
Ask authors/readers for more resources
The androgen receptor (AR) is a major therapeutic target in prostate cancer pharmacology. Progression of prostate cancer has been linked to elevated expression of AR in malignant tissue, suggesting that AR plays a central role in prostate cancer cell biology. Potent therapeutic agents can be precisely crafted to specifically target AR, potentially averting systemic toxicities associated with nonspecific chemotherapies. In this review, we describe various strategies to generate steroid conjugates that can selectively engage AR with high potency. Analogies to recent developments in nonsteroidal conjugates targeting AR are also evaluated. Particular focus is placed on potential applications in AR pharmacology. The review culminates with a description of future prospects for targeting AR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available